Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Loxo Oncology

Evaluate

Thumbnail
February 01, 2023

US approval tracker: January 2023

Thumbnail
April 05, 2019

Big-bucks first quarter masks drop in deal volume

Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.

Article image
Vantage logo
January 10, 2019

JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame

Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.

Article image
Vantage logo
January 09, 2019

As takeover hopes build, 2018 provides a low bar to beat

Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.

Article image
Vantage logo
January 08, 2019

JP Morgan 2019 – development shortcuts pay off for Sage

Despite several changes of direction SAGE-217 comes out positive in postpartum depression, setting Sage Therapeutics up as a takeover target.

Article image
Vantage logo
January 08, 2019

JP Morgan 2019 – Lilly fans the M&A flames with Loxo Oncology deal

Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Vitrakvi and LOXO-195 with Bayer.

Article image
Vantage logo
January 08, 2019

JP Morgan 2019 day one roundup – happy days are here again

The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.

Article image
Vantage logo
December 20, 2018

Early promise comes back to haunt Spectrum

Article image
Vantage logo
November 28, 2018

One more shot at slowing Keytruda’s first-line lung cancer domination

Vantage has today published a detailed report into first-line lung cancer, discussing key upcoming trial readouts and regulatory decisions, and putting into context the…

Article image
Vantage logo
November 27, 2018

Bayer wants top dollar for larotrectinib

Bayer tests what the market will bear for its newly approved therapy for cancers with NTRK mutations.

Article image
Vantage logo
November 15, 2018

Novel drug approvals set to hit a new record in 2018

Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up